News
5h
Zacks.com on MSNMRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric PatientsModerna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...
Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform ...
In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...
StockStory.org on MSN1d
Why Moderna (MRNA) Stock Is Up TodayShares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...
Explore more
The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...
In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...
A Pennsylvania Representative is looking to ban testing mRNA vaccines on domestic animals. Representative Jacob Banta (R-Erie ...
For decades, one of the world’s most contagious diseases was considered eradicated in the U.S. But today, measles is roaring ...
Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results